Product Description

Tecentriq 840 mg Injection contains atezolizumab, a PD-L1 blocking monoclonal antibody used for treating advanced or metastatic cancers including non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), urothelial carcinoma, hepatocellular carcinoma, and melanoma. Tecentriq works by targeting the PD-L1 protein found on cancer cells, which normally helps them evade detection by the immune system. By blocking this protein, Tecentriq reactivates T-cells to identify and destroy cancer cells. It is administered as an intravenous infusion under the supervision of oncology specialists. Macarius Health ensures genuine Tecentriq with proper cold-chain handling and national delivery support.